Physician profile

George E Glosson

Optometrist · Burlington, NC

NPI 1881642882

$761.47

in general payments reported to CMS, 2019-2025

5 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$265.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Bausch & Lomb, A Division of Bausch Health US, LLC $309.63 2019-2020
Coopervision INC. $221.70 2020-2024 Cvi Contact Lens, Myday Contact Lens
Bausch & Lomb Americas INC. $135.29 2023-2024 Infuse, Biotrue One Day
Alcon Vision LLC $58.58 2019
Johnson & Johnson Vision Care, INC. $36.27 2019-2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

George E Glosson

$761.47

in general payments reported 2019-2025

Years
2019-2024
Top company
Bausch & Lomb, A Division of Bausch Health US, LLC

https://glasscript.com/doctor/787079/george-e-glosson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.